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Abstract
Objectives: The purpose of this study was to evaluate the prevalence of autonomic dysfunction in
non-diabetic continuous ambulatory peritoneal dialysis patients and to investigate its risk factors
using the sympathetic skin response.
Methods: We performed a cross-sectional study on 113 non-diabetic continuous ambulatory
peritoneal dialysis patients  using the sympathetic skin response, a non-invasive test to detect
sympathetic sudomotor deficit.
Results: Sixty-six patients (58.4%) showed an abnormal sympathetic skin response suggesting a
sympathetic sudomotor deficit. Patients were then categorized into two groups according to their
sympathetic skin response result. The baseline clinical data, nutritional and dialysis adequacy
indices of the two groups were compared. Patients with an abnormal sympathetic skin response
are significantly older (54.9 ± 12.52 vs 61.79 ± 12.16 years, p=0.004), more malnourished with a
lower albumin (35.79 ± 2.41 vs 33.98 ± 4.92 g/L, p=0.012) and normalized protein nitrogen
appearance values (0.99 ± 0.17 vs 0.93 ± 0.16 g/kg/day, p=0.046). Further, they have a lower
residual renal function as calculated by weekly renal Kt/V (0.63 ± 0.61 vs 0.29 ± 0.35, p=0.001) or
renal creatinine clearance (41.35 ± 40.2 vs 21.96 ± 27.22 L/wk/1.73 m2, p=0.006). Patients with
an abnormal sympathetic skin response are also receiving a smaller dialysis dose as calculated
by the total weekly Kt/V (2.13 ± 0.6 vs 1.83 ± 0.41, p=0.004) or the total creatinine clearance (82.
42 ± 37.34 vs 66.81 ± 25.38 L/wk/1.73 m2, p=0.017).
Conclusion: Based on sympathetic skin response, autonomic dysfunction is common among non-
diabetic continuous ambulatory peritoneal dialysis patients. Patients with autonomic dysfunction
are significantly older, more malnourished, have low residual renal function and are receiving a
smaller dialysis dose. A prospective study is warranted to investigate the reversibility of autonomic
dysfunction after an increment in dialysis dose.
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INTRODUCTION
A number of neurologic disorders have been implicated
in uremia (1), involving the central nervous system,
peripheral nervous system as well as the autonomic
nervous system. Autonomic dysfunction has been
documented in predialysis (2), hemodialysis, peritoneal
dialysis, as well as renal transplant patients. Most data,
however, have been collected in hemodialysis patients
where autonomic dysfunction was observed in 50% of
patients (3,4). Studies of autonomic neuropathy in
continuous ambulatory peritoneal dialysis (CAPD)
patients remain scarce.
Further, the pathogenesis of autonomic neuropathy
remains unknown (5). A number of factors have been
incriminated. Parathyroid hormone (PTH) has been
suggested to be neurotoxic (6). Anemia of uremia may
possibly affect autonomic function (7). Not surprisingly,
other uremic toxins have also been incriminated as
possible factors in the genesis of uremic neuropathy (8).
However, we are not aware of studies comparing the
dialysis dose and other factors to the emergence of uremic
autonomic neuropathy in CAPD patients. There is
increasing evidence that abnormal autonomic
cardiovascular reflexes are associated with poor
prognosis secondary to sudden cardiac death and silent
myocardial infarction (7). Cardiovascular events remain
the leading cause of mortality in patients with end stage
renal failure (9-11). In addition, autonomic dysfunction
is also associated with a number of chronic debilitating
symptoms such as postural dizziness, erectile failure,
esophageal reflux, bloating, early satiety, diarrhea, and
constipation (2). It would be useful to obtain data
regarding the prevalence of autonomic neuropathy in
CAPD patients in Hong Kong as well as identifying
possible factors in predicting the emergence of autonomic
neuropathy for risk stratification and possible therapeutic
maneuvers.
The purpose of this study was to evaluate the prevalence
of autonomic neuropathy in non-diabetic CAPD patients
in one of the major renal units in Hong Kong using the
sympathetic skin response (SSR). We also try to identify
clinical predictive factors for uremic autonomic
neuropathy.
METHOD
Patient selection
This is a cross sectional study. All non-diabetic CAPD
patients being followed up at the Renal Unit of the Alice
Ho Miu Ling Nethersole Hospital were recruited. Patients
were selected using the local renal registry data and those
with diagnosed diabetes mellitus were excluded. The
nature of the study was explained with informed consent
obtained in more than 80% of cases. The examinations
were conducted either between 10:00 a.m. and 12:00
noon, or 2:00 p.m. to 4:00 p.m. All tests were performed
in a quiet room in the outpatient clinic where the
temperature was held constant at 22 to 24oC. All tests
were performed using the Nicolet Viking IV+
electrodiagnostic system with version 4.5 software
(Nicolet Biomedical Inc., Madison, US).
Sympathetic skin response
After a period of rest in the recumbent position, the
patient was trained to produce a reproducible deep cough.
Electrode pairs of 1 cm in diameter were applied to the
dorsal and ventral surfaces of the hand and the foot.
Corresponding grounding electrodes were placed over
the wrist and ankle. Subjects were then asked to perform
a deep cough and the skin potentials recorded. The
procedure was repeated three times at irregular intervals.
A positive response is defined as the presence of an
electrical potential consistent with a SSR in at least one
lead (Fig. 1). A negative response is defined as a total
lack of skin potential when the test is repeated three times
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urea and creatinine. Total body water was calculated
using Watson formula (12). Protein nitrogen appearance
(PNA) was estimated using the method described by
Teehan et al (13) and normalized to body weight. The
equations were described in the Table 1.
Serum levels of urea, creatinine, albumin, PTH levels,
fasting cholesterol,  hemoglobin, and alkaline
phosphatase (ALP) were measured and recorded.
Statistical analysis
Normally distributed data are presented as mean ±
standard deviation. Chi-squared test was used for
categorical data. Comparisons between groups were
performed using two-tailed independent t test for
unpaired data. Statistical calculations were performed
using SPSS software version 9.0 (SPSS Inc., Chicago,
IL).
RESULTS
Patient characteristics
One hundred and thirteen patients on CAPD were
recruited to the study. These included 61 women and 52
men. The cause of end-stage renal failure were
hypertensive nephropathy in 27 (24%) patients,
glomerulonephritis in 19 (17%), immunoglobulin A
nephropathy in 13 (11%), polycystic kidney disease in
eight (7%), obstructive uropathy in 13 (12%), and
unknown in 33 (29%) due to late presentation. The mean
age was 58.9 ± 12.7 years (range, 30-80 years). The mean
duration on CAPD was 2.45 ± 2.31 years (range, 0.15-
20.96 years). The mean weekly total Kt/V achieved was
1.95 ± 0.51 (range, 0.99-4.04) while the mean weekly
renal Kt/V was 0.43 ± 0.5 (range, 0-2.31). The
corresponding total CrCl was 73.08 ± 31.54 L/wk/1.73
m2 and the renal CrCl was 29.75 ± 34.24 L/wk/1.73m2.
Biochemical tests show a mean urea of 19.85 ± 5.98
mmol/L (range, 5.7-39.5 mmol/L), a mean creatinine of
898.11 ± 315.77 µmol/L (range, 336-2058 µmol/L). The
mean serum albumin was 34.73 ± 4.16 g/L (range, 18-
44 g/L), and the mean cholesterol was 5.26 ± 1.34 mmol/
L (range, 2.01-9.84 mmol/L).
Sympathetic skin response
Sympathetic skin response was abnormal in 66 (58.4%)
cases. The baseline clinical data between patients
showing normal/abnormal SSR are shown in Table 2.
There was no significant difference between the two
groups in terms of hemoglobin, PTH, ALP, serum urea,
and creatinine levels. Univariate analysis shows a
significant difference between the two groups in indices
of dialysis dose, nutritional status, and age.
(Fig. 2). A positive response is recorded as normal and a
negative response is recorded as abnormal. All tests were
performed by a nephrologist with training from the chief
neurologist of the hospital.
Dialysis dose calculations and
measurements
Total Kt/V and creatinine clearance (CrCl) were
estimated from 24-hour dialysate and urine recovery of
Figure 1. Actual tracing of a normal sympathetic skin response in
a CAPD patient where the upper and lower tracing represents skin
potentials of the left foot and hand respectively.
Figure 2. Actual tracing of a negative SSR showing no
electrodermal activity on both the hand and foot of a CAPD patient.
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Patients with an abnormal SSR are significantly older
(54.9 ± 12.5 vs 61.8 ±12.2 years, p=0.004). They have
poorer nutritional indices, including albumin (35.8 ± 2.
4 vs 34.0 ± 4.9 g/L, p=0.012) and normalized PNA
(nPNA) values (0.99 ± 0.17 vs 0.93 ± 0.16, p=0.046).
There is a trend towards a longer duration on CAPD in
the abnormal SSR group, but this did not reach statistical
significance (2.79 ± 2.70 vs 1.97 ± 1.54 years, p=0.064).
Further, patients with an absent SSR also have a
significantly lower residual renal function as calculated
by the renal Kt/V (0.63 ± 0.61 vs 0.29 ± 0.35, p=0.001)
and the renal CrCl (41.4 ± 40.2 vs 22 ± 27.2 L/wk/1.73
m2, p=0.006). Patients with an absent SSR also receive
a significantly lower dialysis dose as calculated by
weekly total Kt/V (2.13 ± 0.60 vs 1.83 ± 0.41, p=0.004)
as well as the total CrCl (82.4 ± 37.3 vs 66.8 ± 25.4 L/
wk/1.73 m2, p=0.017). No significant association was
noted on chi-square test between the response to SSR
and medication intake that might affect autonomic
function testing (p=0.065).
DISCUSSION
Skin potential recordings have been used to detect
sympathetic sudomotor deficit in central autonomic
neuropathies and peripheral neuropathies (14,15). Using
standard electromyographic equipment, the electrical
potential difference between the skin over the front and
back of the hand and foot is measured via surface
electrodes after a stimulus. The stimuli act via increasing
sympathetic cholinergic activity to the sweat glands. The
evoked electrodermal activity consists of a biphasic
potential consisting of an initial negativity followed by
Measurement Calculation
Total weekly Kt/V Total weekly Kt/V = weekly peritoneal Kt/V + Weekly renal Kt/V
Weekly peritoneal Kt/V = [(TeU/Userum)/TBW] X 7
Weekly renal Kt/V = [(Uurine/Userum)/TBW] X 7
Total weekly CrCl, L/week/1.73 m2 Total weekly CrCl, L/week/1.73 m2 = Weekly peritoneal CrCl + Weekly renal CrCl
Weekly peritoneal CrCl, L/week/1.73 m2 = [(TeCr/Crserum)] X (1.73/BSA) X 7
Weekly renal CrCl, L/week/1.73 m2 = {[(Uurine/Userum) + (Crurine/Crserum)]/2} X 7 X (1.73/BSA)
Total body water by Watson’s formula Total body water
For male: 2.447 – 0.09516 X A + 0.1074 X H + 0.3362 X BW
For female: –2.097 + 0.1069 X H + 0.2466 X BW
Body surface area by duBois’ formula Body surface area = 0.007184 X BW 0.425 X H 0.725
Normalized protein nitrogen appearance rate (ref no. 13): nPNA = {6.25 [(Uurine + TeU) X
28/1000 + 1.81 + 0.031 X BW]}/BW
A = age (year); H = height (cm); BW = body weight with dry abdomen (kg); TeCr = total amount of effluent creatinine (µmol/d); TeU = total
amount of effluent urea (mmol/d); Userum = serum urea (mmol/L); Uurine = urinary urea excretion µmmol/d); Crserum = serum creatinine (µmmol/
L); Crurine = urinary creatinine excretion (µmol/d); BSA = body surface area; TBW = total body water (L); nPNA = normalized protein nitrogen
appearance rate
Table 1. Dialysis dose calculations and measurements.
Normal SSR (n = 47) Abnormal SSR (n = 66) p value
Age, year 54.90 ± 12.52 61.79 ± 12.16 0.004*
M/F 23/24 29/37 0.599
Hemoglobin, g/dL 9.95 ± 1.54 9.52 ± 1.77 0.187
Albumin, g/L 35.79 ± 2.41 33.98 ± 4.92 0.012*
PTH 42.23 ± 36.73 54.27 ± 52.41 0.166
ALP, IU/L 91.43 ± 42.70 166.36 ± 312.63 0.126
nPNA, g/kg/d 0.99 ± 0.17 0.93 ± 0.16 0.046*
Duration on CAPD, year 1.97 ± 1.54 2.79 ± 2.70 0.064
Weekly renal Kt/V 0.63 ± 0.61 0.29 ± 0.35 0.001*
Weekly total Kt/V 2.13 ± 0.60 1.83 ± 0.41 0.004*
Renal CrCl, L/wk/1.73 m2 41.35 ± 40.20 21.96 ± 27.22 0.006*
Total CrCl, L/wk/1.73 m2 82.42 ± 37.34 66.81 ± 25.38 0.017*
Cholesterol, mmol/L 5.22 ± 1.03 5.28 ± 1.53 0.795
Urea, mmol/L 19.53 ± 5.80 20.07 ± 6.14 0.637
Creatinine, µmol/L 876.91 ± 345.90 912.97 ± 294.60 0.551
*p<0.05.
Table 2. Sympathetic skin response: baseline clinical characteristics and investigation results between the normal and abnormal group.
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a positive potential (16). The neuroanatomic substrate
underlying the SSR in humans remains unknown.
Sympathetic skin response has been used for evaluation
of autonomic dysfunction in renal failure patients (17,
18), and most recently by Zakrzewska-Pniewska and
Jedras (19) who suggested that SSR may become a useful
technique for the assessment of autonomic dysfunction
in uremic patients.
The major advantage of the sympathetic skin response
is its simplicity in operation and its noninvasiveness. It
can be performed using standard electromyographic
equipment. There are, however, a number of dis-
advantages. It is widely considered that SSR can exhibit
an enormous amount of variability though Levy et al
(20) has recently demonstrated a low coefficient of
variation. SSR exhibits habituation on repetitive stimuli
(14,21) and hence, stimuli are applied at irregular
intervals of more than 30 seconds to assure reproducibility
of the SSR. Sympathetic skin response latencies were
noted to be prolonged in patients with neuropathies,
though a significant overlap exists between normal
subjects and those with neuropathies (22,23). No clear
consensus is available as to what constitutes an abnormal
SSR (16). There is, however, general agreement that a
loss of SSR is abnormal (15,16). Further, simplification
of the definition of an abnormal SSR allows rapid
screening of autonomic dysfunction to be performed and
reduces the learning curve of trained personnel for the
performance of the test. It is generally agreed that cough
is a more robust stimuli (24). Hence, in this study, we
have aimed to formulate a robust, rapid as well as a
clinically accessible test of autonomic neuropathy in
CAPD patients for nephrologists.
In our study, CAPD patients with an absent SSR
suggestive of autonomic neuropathy are significantly
older (54.9 ± 12.5 vs 61.8 ± 12.2 years, p=0.004) and
have been on dialysis for a longer time, although the
latter did not reach statistical significance. This is not
surprising since, SSR diminishes with age. Fifty percent
of normal subjects above 60 years of age have absent
plantar SSR (25), partly explained by the diminution of
density of sweat glands in aging (26).
The SSR is absent in a number of axonal and
demyelinating neuropathies including diabetes and
uremia. In our study group, 58.4% of CAPD patients
display an absent SSR. This is in concordance to previous
literature of the prevalence of autonomic neuropathy in
hemodialysis patients by the use of cardiovascular tests
(3,4). An abnormal SSR was noted in 66% to 80% of
well-established symptomatic diabetic neuropathy (27,
28). Sympathetic skin response has been less well studied
in CAPD patients.
Parathyroid hormone has been suggested to be neurotoxic
in uremic patients (6). However, a number of studies
have failed to demonstrate that PTH is an important factor
(29,30). In concordance with these studies, we have not
been able to notice a statistically significant relationship
in our autonomic function tests that was performed on
113 CAPD patients. In addition to PTH, it is perhaps not
unreasonable to suspect some form of uremic toxins as
the incriminating agent. However, few studies are
available to address this issue. Laaksonen et al (31) has
noted an improvement in heart rate variability time
domain measures in hemodialysis patients when Kt/V
over 1.2 as well as a progressive deterioration of
autonomic neuropathy when Kt/V below 0.85. More
importantly, emerging data is suggesting the superiority
residual renal function as compared with peritoneal
clearance (32). In this study, both indices of residual renal
function as well as the total dialysis dose were found to
be significantly lower in the group of patients with an
absent SSR suggesting that as the residual renal function
declines with time, the incidence of autonomic
dysfunction increases.
There are, however, a number of limitations in this study.
An absent SSR is not necessarily indicative of abnormal
sympathetic sudomotor function as it may be dependent
on the integrity of peripheral nerve afferents or trophic
skin changes that occur with long-standing neuropathies.
Concomitant nerve conduction tests have not been
performed in this study. It would have been preferable
to include a battery of autonomic function tests such as
Valsalva maneuver, R-R interval variation and blood
pressure response to standing. The use of statistical
models such as multivariate analysis would be useful in
a follow-up study.
In summary, evidence of sympathetic dysfunction is
present in 58.4% of non-diabetic CAPD patients in our
dialysis unit. Non-diabetic CAPD patients with
sympathetic autonomic dysfunction as evidenced by an
absent SSR are significantly older, more malnourished,
retain a lower residual renal function and at the same
time receive a smaller dialysis dose. Prospective study
is warranted to investigate the reversibility of autonomic
dysfunction after an increment in dialysis dosage.
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